We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+26.99%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$12.5B
AUM Growth
+$844M
Cap. Flow
-$1.62B
Cap. Flow %
-12.95%
Top 10 Hldgs %
33.14%
Holding
137
New
32
Increased
25
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$331M
2
AON icon
Aon
AON
+$321M
3
WUBA
58.com Inc
WUBA
+$256M
4
BMY icon
Bristol-Myers Squibb
BMY
+$217M
5
TIF
Tiffany & Co.
TIF
+$191M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$1.65B
2
CI icon
Cigna
CI
+$142M
3
FIS icon
Fidelity National Information Services
FIS
+$135M
4
GD icon
General Dynamics
GD
+$132M
5
WAB icon
Wabtec
WAB
+$113M

Sector Composition

Rank Sector Weight
1 Healthcare 42.53%
2 Communication Services 18.4%
3 Technology 10.42%
4 Financials 7.52%
5 Industrials 3.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
51
Grifois
GRFS
$5.4B
$56.8M 0.45%
3,113,222
– –
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
$56.7M 0.45%
+900,000
New +$49.5M
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
$54M 0.43%
2,000,000
-250,000
-11% -$6.9M
ZNTL icon
54
Zentalis Pharmaceuticals
ZNTL
$302M
$47.6M 0.38%
+991,174
New +$38M
GBIO
55
DELISTED
Generation Bio
GBIO
$44.5M 0.36%
+211,882
New +$47.2M
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.44B
$44.1M 0.35%
2,500,000
+1,000,000
+67% +$12.5M
EFX icon
57
Equifax
EFX
$21.4B
$43.9M 0.35%
255,344
-122,931
-32% -$18.2M
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$42.7M 0.34%
715,000
-285,000
-29% -$15.2M
UTHR icon
59
United Therapeutics
UTHR
$23.1B
$42.4M 0.34%
350,000
-15,000
-4% -$1.69M
TVRD
60
Tvardi Therapeutics
TVRD
$23.4M
$39.3M 0.31%
63,889
– –
LNTH icon
61
Lantheus
LNTH
$6.59B
$37.7M 0.3%
+2,634,999
New +$34.8M
CYTK icon
62
Cytokinetics
CYTK
$10.4B
$35.4M 0.28%
1,500,000
+875,000
+140% +$16.4M
SAGE
63
DELISTED
Sage Therapeutics
SAGE
$35.3M 0.28%
850,000
+175,000
+26% +$6.35M
ARWR icon
64
Arrowhead Research
ARWR
$12.4B
$34.6M 0.28%
800,000
-200,000
-20% -$7.06M
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$33.2M 0.27%
+1,844,757
New +$25.7M
AMRS
66
DELISTED
Amyris Inc.
AMRS
$29.9M 0.24%
+7,009,527
New +$23.3M
TGTX icon
67
TG Therapeutics
TGTX
$7.62B
$29.2M 0.23%
+1,500,000
New +$24.2M
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$28.6M 0.23%
2,100,000
+45,514
+2% +$627K
FSCT
69
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$27.7M 0.22%
1,305,000
+430,000
+49% +$11.7M
PLRX icon
70
Pliant Therapeutics
PLRX
$65M
$27.6M 0.22%
+850,801
New +$22.6M
TECX
71
Tectonic Therapeutic
TECX
$606M
$27.5M 0.22%
131,250
-12,500
-9% -$2.58M
KPTI icon
72
Karyopharm Therapeutics
KPTI
$48M
$25.3M 0.2%
89,000
– –
ADAP
73
DELISTED
Adaptimmune Therapeutics
ADAP
$25M 0.2%
+2,500,000
New +$15.7M
RCUS icon
74
Arcus Biosciences
RCUS
$3.64B
$24.7M 0.2%
+1,000,000
New +$27M
BRMK
75
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$22.6M 0.18%
2,391,536
– –
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Farallon Capital Management held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Farallon Capital Management withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Farallon Capital Management opened a new position in T-Mobile US worth $360M.

  • Farallon Capital Management's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
  • Farallon Capital Management added most to Blackstone in Q2 2020, an estimated $125M increase.
  • Farallon Capital Management's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
  • Farallon Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
  • Farallon Capital Management's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
  • Farallon Capital Management opened 32 new positions and closed 18 in Q2 2020.
  • Farallon Capital Management's portfolio value rose 7.2% quarter-over-quarter to $12.5B.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.